Edition:
United States

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

7.80USD
25 May 2017
Change (% chg)

$-0.35 (-4.29%)
Prev Close
$8.15
Open
$8.25
Day's High
$8.25
Day's Low
$7.78
Volume
125,305
Avg. Vol
165,656
52-wk High
$8.57
52-wk Low
$2.65

Latest Key Developments (Source: Significant Developments)

Sangamo receives fast track designation from FDA for SB-525
Tuesday, 16 May 2017 07:30am EDT 

May 16 (Reuters) - Pfizer Inc -:Sangamo receives fast track designation from the FDA for sb-525 investigational hemophilia a gene therapy.Sangamo Therapeutics Inc says data from phase 1/2 clinical trial evaluating sb-525 in adults with hemophilia a expected in late 2017 or early 2018.  Full Article

Sangamo Therapeutics reports Q1 revenue $3.4 million
Wednesday, 10 May 2017 04:01pm EDT 

May 10 (Reuters) - Sangamo Therapeutics Inc :Sangamo Therapeutics reports first quarter 2017 financial results.Q1 revenue $3.4 million versus I/B/E/S view $4.3 million.Q1 loss per share $0.23.Q1 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy
Wednesday, 10 May 2017 04:01pm EDT 

May 10 (Reuters) - Pfizer Inc :Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy.Sangamo Therapeutics Inc says under terms of collaboration agreement, Sangamo will receive a $70 million upfront payment from Pfizer.Sangamo Therapeutics Inc says Sangamo will be responsible for conducting SB-525 phase 1/2 clinical study and certain manufacturing activities.Sangamo -Pfizer will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525.Sangamo Therapeutics Inc says Sangamo is eligible to receive potential milestone payments of up to $475 million.Sangamo Therapeutics Inc says Sangamo will also receive tiered double-digit royalties on net sales.Sangamo Therapeutics Inc says additionally, Sangamo will be collaborating with Pfizer on manufacturing and technical operations utilizing viral delivery vectors.  Full Article

Sangamo Therapeutics says special regulatory designations from FDA for 3 clinical programs
Thursday, 4 May 2017 08:00am EDT 

May 4 (Reuters) - Sangamo Therapeutics Inc :Sangamo therapeutics announces special regulatory designations from the fda for three clinical programs.Sangamo therapeutics inc- rare pediatric disease designation for sb-913 in vivo genome editing treatment for mps ii.Sangamo therapeutics inc- orphan drug designation for sb-525 cdna gene therapy for hemophilia a.Sangamo therapeutics inc- fast track designation for sb-fix in vivo genome editing treatment for hemophilia b.  Full Article

Sangamo Therapeutics receives orphan drug designation from the FDA for SB-913 genome editing treatment for MPS II
Wednesday, 1 Mar 2017 08:30am EST 

Sangamo Therapeutics Inc : Sangamo Therapeutics receives orphan drug designation from the fda for sb-913 genome editing treatment for mps ii . Sangamo therapeutics inc - in 2017, sangamo is conducting phase 1/2 clinical trial evaluating sb-913 as an in vivo genome editing treatment for mps ii . Sangamo Therapeutics Inc - sangamo has also submitted an application to FDA for rare pediatric disease designation for sb-913 .Sangamo Therapeutics- data from studies,from clinical trial for fourth lead program, sb-525, a gene therapy approach for hemophilia a, are expected in late 2017 or early 2018.  Full Article

Sangamo therapeutics Q4 loss per share $0.14
Tuesday, 28 Feb 2017 07:00am EST 

Sangamo Therapeutics Inc : Sangamo Therapeutics reports fourth quarter and full year 2016 financial results . Q4 revenue $8.9 million versus $9.1 million . Q4 loss per share $0.14 . Sees FY 2017 revenue $14 million to $19 million . Q4 revenue view $3.9 million -- Thomson Reuters I/B/E/S . Q4 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S . Sangamo Therapeutics Inc says expects that its cash, cash equivalents and marketable securities will be at least $60 million at end of 2017 .FY2017 revenue view $22.5 million -- Thomson Reuters I/B/E/S.  Full Article

Sangamo Therapeutics announces CFO succession
Monday, 27 Feb 2017 04:30pm EST 

Sangamo Therapeutics Inc : Sangamo Therapeutics announces chief financial officer succession . Says Kathy Yi appointed cfo .Sangamo Therapeutics Inc- Kathy Yi succeeds H. Ward Wolff, who will be retiring from company in early march.  Full Article

Sangamo says receives rare pediatric disease designation from FDA for SB-318
Monday, 27 Feb 2017 08:00am EST 

Sangamo Therapeutics Inc : Sangamo therapeutics receives rare pediatric disease designation from fda for sb-318 in vivo genome editing therapeutic for mps i . Sangamo therapeutics inc - in 2017, co is conducting a phase 1/2 clinical trial evaluating sb-318 for mps i .Sangamo therapeutics-submitted application to fda for odd,rare pediatric disease designation for sb-913;co's in vivo genome editing program for mps ii.  Full Article

Sangamo Therapeutics receives orphan drug designation from the FDA for SB-318 genome editing treatment for MPS I
Wednesday, 11 Jan 2017 07:30am EST 

Sangamo Therapeutics Inc : Sangamo Therapeutics receives orphan drug designation from the FDA for SB-318 genome editing treatment for MPS I . Sangamo Therapeutics says data from studies and from planned clinical trial for a fourth lead program, SB-525 are expected in late 2017 or early 2018 .Sangamo Therapeutics says in 2017, plans to conduct first in vivo genome editing clinical trials including phase 1/2 studies for three programs.  Full Article

Sangamo Biosciences enters into a sales agreement with Cowen and Co to sell up to $75 mln of stock
Wednesday, 7 Dec 2016 05:31pm EST 

Sangamo Biosciences Inc :Sangamo Biosciences Inc-On Dec 7, co entered into a sales agreement with Cowen and Company to sell up to $75.0 million of stock, par value $0.01 per share.  Full Article

More From Around the Web

Photo

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

NEW YORK U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront.